Maximum a posteriori Bayesian estimation of epirubicin clearance by limited sampling

British Journal of Clinical Pharmacology

Volumn 57, Issue 6, 2004, Pages 764-772

  Ralph, Lorraine D ^a,e   Thomson, Alison H ^a,b   Dobbs, Nicola A ^c   Twelves, Chris ^d  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e IQVIA   (United States)

Author keywords

Epirubicin; Limited sampling; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; EPIRUBICIN;

ADULT; ADVANCED CANCER; AGED; ANALYTICAL ERROR; ARTICLE; BAYES THEOREM; BLOOD SAMPLING; BREAST CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; EXPERIMENTAL MODEL; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREDICTION; PRIORITY JOURNAL; SIMULATION;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; BAYES THEOREM; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EPIRUBICIN; HUMANS; MIDDLE AGED; NEOPLASMS;

EID: 2942605811     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02084.x     Document Type: Article

References (21)

1. Plosker GL, Faulds D. Epirubicin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 1993; 45: 788-856.
2. Coukell AJ, Faulds D. Epirubicin: An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer. Drugs 1997; 53: 453-82.
3. Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol 1988; 6: 1321-7.
4. Dobbs NA, Twelves CJ, Gillies H, James CA, Harper PG, Rubens RD. Gender effects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol 1995; 36: 473-6.
5. Camaggi CM, Strocchi E, Tamassia V, et al. Pharmacokinetic studies of 4′-epi-doxorubicin in cancer patients with normal and impaired renal function and with liver metastases. Cancer Treat Rep 1982; 66: 1819-24.
6. Kerr DJ, Graham J, Cummings J, et al. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 1986; 18: 239-42.
7. Danesi R, Conte PF, Del Tacca M. Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer. Clin Pharmacokinet 1999; 37: 195-211.
8. Jakobsen P, Basholt L, Dalmark M, et al. A randomised study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement. Cancer Chemother Pharmacol 1991; 28: 465-9.
9. Hu O, Chang S, Jame J, Chen K. Pharmacokinetic and pharmacodynaimc studies with 4′-epi-doxorubicin in nasopharyngeal carcinoma patients. Cancer Chemother Pharmacol 1989; 24: 332-7.
10. Eksborg S, Hardell L, Bengtsson N, Sjodin M, Elfsson B. Epirubicin as a single agent therapy for the treatment of breast cancer - a pharmacokinetic and clinical study. Med Oncol Tumor Pharmacother 1992; 9: 75-80.
11. Pharmorubicin Summary of Product Characteristics. http://emc.medicines. org.uk/. Document last updated on the eMC15 April 2003.
12. Ralph LD, Thomson AH, Dobbs NA, Twelves C. A population model of epirubicin pharmacokinetics and application to dosage guidelines. Cancer Chemother Pharmacol 2003; 52: 34-40.
13. Rousseau A, Marquet P, Debord J, Sabot C, Lachatre S. Adaptive control methods for the individualisation of anticancer agents. Clin Pharmacokinet 2000; 38: 315-53.
14. Jakobsen P, Steiness E, Bastholt L, et al. Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer. Cancer Chemother Pharmacol 1991; 28: 63-8.
15. Box CEP, Lucas HL. Design of experiments in non-linear situations. Biometrika 1959; 46: 77-90.
16. Dobbs NA, Twelves CJ, Rizzi P, et al. Epirubicin in hepatocellular carcinoma: pharmacokinetics and clinical activity. Cancer Chemother Pharmacol 1994; 34: 405-10.
17. Dobbs NA, Twelves CJ. Measurement of epidoxorubicin and its metabolites by high-performance liquid chromatography using an advanced automated sample processor. J Chromatogr 1991; 572: 211-7.
18. D'Argenio DZ, Schumitzky A. ADAPT II User's Guide: Pharmacokinetic/ Pharmacodynamic Systems Analysis Software. Biomedical Simulations Resource, Los Angeles, 1997.
19. Beal SL, Sheiner LB. NONMEM (User's Guide), Parts 1-VII Technical Report. University of California, San Francisco, 1992.
20. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-12.
21. Sun H, Ette EI, Ludden TM. On the recording of sample times and parameter estimation from repeated measures pharmacokinetic data. J Pharmacokin Biopharm 1996; 24: 637-50.